Skip to content
DataLookout
Menu

DUETNCT07946367

Dual-targeting of B & T Cell Pathways Evaluation Trial

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

To evaluate the initial safety and tolerability of DFI205 in adults with SARDs
Timeframe: Up to 1 year post-dosing
To monitor immune reconstitution after completion of dosing with DFI205
Timeframe: Up to 1 year post-dosing
To monitor immune response to DFI205
Timeframe: Up to 1 year post-dosing

Secondary (4)

To evaluate the ability of DFI205 to induce an objective response in adults with RA
To evaluate the ability of DFI205 to induce an objective response in adults with SLE
To evaluate the ability of DFI205 to induce an objective response in adults with SSc
To evaluate the ability of DFI205 to induce an objective response in adults with IIM

Arms and interventions

Phase 1 Single Ascending Dose EscalationExperimental

Intravenous (IV) infusion of DFI205 at ascending dose levels.

Phase 2a Multi-DoseExperimental

DFI205 monthly IV infusions at the recommended Phase 2 dose

Drugs: DFI205 bispecific antibody

Sites

1 site in 1 country

  • Universitaetsklinikum Erlangen AöRErlangen, Germany